Drug Profile
Influenza A virus vaccine H5N1 - PaxVax
Alternative Names: Ad4-H5-Vtn; PXVX-0103Latest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator PaxVax
- Class Influenza A virus H5N1 vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Influenza A virus H5N1 subtype
Most Recent Events
- 04 Oct 2018 PaxVax has been acquired by Emergent BioSolutions
- 16 Jul 2016 No recent reports of development identified for phase-I development in Influenza-A-virus-H5N1-subtype(Prevention, In volunteers) in USA (PO, Capsule)
- 31 Jan 2013 Immunogenicity data from a phase I trial in healthy volunteers released by PaxVax